Peimin Yu

Peimin Yu

Auto-generated profile, based on publicly available information

Peimin Yu

Huashan Hospital, Fudan University, Shanghai, China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 October 2025 in Epilepsia
Verified
Journal Article
Open access
Sang Kun LeeSang Kun Lee
Sang Kun Lee
PYPeimin Yu
Peimin Yu
ECEunyeong Choe
Eunyeong Choe
LFLouis Ferrari
Louis Ferrari
KHKyoung Heo
Kyoung Heo
SMSunita N. Misra
Sunita N. Misra
Objectives: This randomized, double‐blind, placebo‐controlled study (NCT04557085), conducted in China, Japan, and the Republic of Korea, evaluated the efficacy and safety of adjunctive cenobamate in patients with uncontrolled focal seizures. Methods: Adults 18–70 years of age with ≥8 seizures (focal aware motor, focal impaired awareness, or focal to bilateral tonic–clonic) during an 8‐week baseline, despite treatment with 1–3 antiseizure medications (ASMs), were randomized 1:1:1:1 to placebo or cenobamate 100, 200, or 400 mg/day. The study included an 18‐week titration phase and a 6‐week maintenance phase. The primary efficacy analysis was a hierarchical step‐down comparison of the percent change from baseline in 28‐day seizure frequency vs placebo during the maintenance phase for cenobamate 200, then 400, and then 100 mg/day. Results: Among 519 patients randomized, 446 received ≥1 dose of study drug and had ≥1 efficacy measure during the maintenance phase (placebo, n = 117; 100 mg/day, n = 113; 200 mg/day, n = 113; and 400 mg/day, n = 103). Median percent change in seizure frequency during the maintenance phase was −25.9% for placebo vs −42.6%, −78.3%, and −100% for cenobamate 100, 200, and 400 mg/day, respectively (all p 's < .001). During the 12‐week period encompassing the last 6 weeks of titration and the 6‐week maintenance phase (secondary outcome), the median percent change in seizure frequency was −20.1% for placebo vs −42.6%, −77.1%, and −89.2% for cenobamate 100, 200, and 400 mg/day, respectively. Seizure‐free rates during the maintenance phase were 2.6% of patients for placebo vs 12.4%, 30.1%, and 52.4% for cenobamate 100, 200, and 400 mg/day, respectively, and during the 12‐week period were 0.8% for placebo vs 8.5%, 19.7%, and 30.6% for the cenobamate groups. The most common treatment‐emergent adverse events in cenobamate patients (≥20%) were dose‐related dizziness and somnolence. Significance: Cenobamate 100, 200, and 400 mg/day reduced focal seizures in Asian patients in a dose‐related fashion and was generally well tolerated.

28 August 2026 in Epilepsia
Verified
Journal Article
Open access
PDF file
Sang Kun LeeSang Kun Lee
Sang Kun Lee
PYPeimin Yu
Peimin Yu
ECEunyeong Choe
Eunyeong Choe
LFLouis Ferrari
Louis Ferrari
KHKyoung Heo
Kyoung Heo
SMSunita N. Misra
Sunita N. Misra
Objective: This study was undertaken to assess long‐term efficacy, safety, and tolerability of adjunctive cenobamate in an open‐label extension (OLE) of a randomized, double‐blind, placebo‐controlled, dose–response study (NCT04557085; YKP3089C035 [Study C035]) in Asian patients with uncontrolled focal seizures. Methods: Patients 18–70 years old with uncontrolled focal seizures despite treatment with 1–3 antiseizure medications who completed the 24‐week double‐blind treatment period ( n = 425) at cenobamate doses of 100, 200, or 400 mg/day or placebo could enter a 52‐week OLE. All patients were converted to a cenobamate dose of 400 mg/day during a 20‐week double‐blind conversion phase and then entered a 32‐week open‐label maintenance phase at a starting dose of 300 mg/day. Results: Among the 410 patients who entered the double‐blind conversion phase, 357 (263 and 94 originally randomized to cenobamate and placebo, respectively) entered the OLE maintenance phase. The median percent focal seizure frequency reduction from double‐blind baseline for patients who received at least one dose of cenobamate during the 32‐week maintenance phase was 83.6%. The percent of patients achieving ≥50% and 100% responses during the maintenance phase was 75.1% and 25.5%, respectively. Among patients entering the OLE, 84.6% (347/410) completed the 52 weeks of treatment with cenobamate. The most commonly occurring treatment‐emergent adverse events (TEAEs) during the entire OLE were dizziness, somnolence, γ‐glutamyl transferase (GGT) increase, and COVID‐19 infection. GGT increase was not associated with any clinically significant findings. Serious TEAEs occurred in 11.7% of patients (48/410). There were no deaths and no cases of DRESS (drug reaction with eosinophilia and systemic symptoms) syndrome reported. Significance: The high long‐term seizure frequency reductions, including a 100% responder rate of 25.5%, were consistent with previous long‐term cenobamate efficacy. The OLE safety profile was also generally consistent with the known cenobamate safety profile, with no new safety signals identified. These results support the use of cenobamate in adult Asian patients with uncontrolled focal seizures.

3 November 2026 in Neurology and Therapy
Verified
Journal Article
Open access
PDF file
PYPeimin Yu
Peimin Yu
XWXintong Wu
Xintong Wu
LCLing Chen
Ling Chen
ECEunyeong Choe
Eunyeong Choe
LFLouis Ferrari
Louis Ferrari
SMSunita N. Misra
Sunita N. Misra
Introduction To evaluate adjunctive cenobamate efficacy by focal seizure subtype during the open-label extension (OLE) of a phase 3 randomized, double-blind, placebo-controlled study (C035) in Asian patients with focal seizures. Methods Patients aged 18–70 years old with uncontrolled focal seizures despite treatment with 1–3 antiseizure medications who completed the double-blind study (n = 425) could enter the 52-week OLE, comprising a 20-week blinded conversion from placebo or 100, 200, or 400 mg/day cenobamate to a target cenobamate dose of 400 mg/day before entering a 32-week open-label maintenance phase at 300 mg/day. Percent change from double-blind baseline in 28-day seizure frequency and responder rates (e.g., ≥ 50% reduction from baseline) for focal preserved consciousness with observable manifestations (FPC), focal impaired consciousness (FIC), or focal to bilateral tonic-clonic (FBTC) seizure subtypes were assessed in the open-label maintenance phase efficacy population (OLE-EM, ≥ 1 dose of study drug and any seizure data during the open-label maintenance phase). Safety and tolerability were assessed. Results Among patients who entered the OLE, 357/410 (263 originally randomized to cenobamate; 94 who converted from placebo to cenobamate) were included in the OLE-EM population. Median percent seizure frequency reductions were 84.5% for FPC (n = 65), 83.0% for FIC (n = 301), and 100% for FBTC (n = 94) in the OLE-EM population. For FPC, FIC, and FBTC subtypes, ≥ 50% responder rates were 75.4%, 73.8%, and 84.0%, respectively, and 100% responder rates were 23.1%, 28.2%, and 58.5%. Among patients entering the OLE, 84.6% (347/410) completed the 52 weeks of treatment with cenobamate. The most common treatment-emergent adverse events were dizziness, somnolence, gamma-glutamyl transferase increased, and COVID-19 infection. Conclusions During the C035 OLE maintenance phase, high seizure frequency reductions were seen for FPC, FIC, and FBTC focal seizure subtypes. Cenobamate was generally well tolerated, and the results were consistent with the double-blind treatment study. Graphical abstract available for this article. Trial Registration NCT04557085 (registered September 14, 2020). Graphical Abstract